Rui Zixuan, Mehdizadeh Sepehr, Abasi Mozhgan, Pilehvar Younes
Sir Run Run Hospital Nanjing Medical University, Nanjing, China.
Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran.
J Robot Surg. 2025 Jul 14;19(1):390. doi: 10.1007/s11701-025-02550-8.
Nanorobotics is catalyzing a paradigm shift in GI surgery by synergizing nanoscale engineering, synthetic biology, and intelligent computation to create a novel frontier in precision medicine. This review critically discusses the most recent experimental breakthroughs in surgical nanorobots-from bioinspired actuation to programmable materials to autonomous tumor ablation to closed-looped therapeutic feedback-and charts their development from static constructions to intelligent agents with the ability to navigate the dynamic gastrointestinal (GI) environment. Systematically, we review how nanorobots integrate with artificial intelligence (AI)-fortified platforms, overcome GI-specific obstacles, and can facilitate site-specific intervention with spatiotemporal precision. Based on state-of-the-art preclinical models, organoid studies in humans, and in vivo deployment, we analyze biodegradability, pharmacokinetics, and regulatory readiness in pursuit of first-in-human trials. Aside from technical innovation, this review also addresses grand challenges in autonomy, off-target control, and ethical-legal frameworks, calling for an integrated, cross-specialty format to facilitate clinical translation. In visualizing neural-controlled nanorobots, self-healing machines, and living biosensor networks, we outline the pathway towards intelligent, minimally invasive surgery at the molecular level. This work posits surgical nanorobotics not as an incremental innovation but as a transformative axis for convergent surgical therapeutics in the next generation. It is an academic wake-up call for the strategic coming of age in this field from experimental brilliance to translational inevitability.
纳米机器人技术正在通过整合纳米尺度工程、合成生物学和智能计算,在胃肠外科领域引发一场范式转变,从而开创精准医学的全新前沿。本综述批判性地讨论了外科纳米机器人的最新实验突破——从仿生驱动到可编程材料,从自主肿瘤消融到闭环治疗反馈——并梳理了它们从静态结构发展成为能够在动态胃肠道环境中导航的智能主体的过程。我们系统地回顾了纳米机器人如何与人工智能强化平台整合、克服胃肠道特有的障碍,以及如何以时空精度促进特定部位的干预。基于最先进的临床前模型、人体类器官研究和体内部署,我们分析了生物降解性、药代动力学以及推进首次人体试验所需的监管准备情况。除了技术创新,本综述还探讨了自主性、脱靶控制和伦理法律框架等重大挑战,呼吁采用综合、跨专业的形式来推动临床转化。在设想神经控制的纳米机器人、自愈机器和活体生物传感器网络时,我们勾勒了在分子水平上实现智能、微创手术的途径。这项工作认为外科纳米机器人技术并非渐进式创新,而是下一代融合手术治疗的变革性轴心。这是一次学术警钟,警示该领域要从实验卓越迈向转化必然性,实现战略成熟。